Home » FDA Cites Pfizer Subsidiary for Lax Oversight, Quality Failures
FDA Cites Pfizer Subsidiary for Lax Oversight, Quality Failures
Pfizer subsidiary Meridian Medical Technologies is under continued pressure from the FDA to improve oversight and quality at its Missouri plants. The agency has published three 483s it has issued to the company’s plants in St. Louis and Brentwood, Mo., over the last two years, citing them for failing to audit suppliers, inadequate testing of incoming raw materials, poor batch records and other quality problems.
Washington Drug Letter
Drugs Inspections and Audits Quality Regulatory AffairsWashington Drug Letter
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May